Allergy Therapeutics leverages major shareholders to enter Latin America
This article was originally published in Scrip
Allergy Therapeutics is kick-starting its push into Latin America, the "easiest route to reach the emerging markets," by leveraging its major shareholders, the Recalcine Group, Manuel Llobet, the company's CEO, told Scrip.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.